19 results
6-K
EX-99.1
TAK
Takeda Pharmaceutical Company Limited
29 May 24
Current report (foreign)
6:24am
TAK-755 prophylactic treatment. TAK-755 also reduced the incidence of thrombocytopenia by 60%, as compared to plasma-based therapy (hazard ratio [HR … for the PFS ITT (intent-to-treat) population (n=400), the hazard ratio (HR) was 0.65 (95% confidence interval [CI]: 0.50-0.84; p=0.0007); the median
6-K
TAK
Takeda Pharmaceutical Company Limited
2 Feb 24
Current report (foreign)
6:16am
of thrombocytopenia by 60%, as compared to plasma-based therapy (hazard ratio [HR] 0.40; 95% confidence interval [CI]; 0.3- 0.7). Treatment-emergent … ), at a median follow-up of 14.3 months for the PFS ITT (intent-to-treat) population (n=400), the hazard ratio (HR) was 0.65 (95% confidence interval [CI
6-K
TAK
Takeda Pharmaceutical Company Limited
30 Oct 23
Current report (foreign)
6:02am
by 60%, as compared to plasma-based therapy (hazard ratio [HR] 0.40; 95% confidence interval [CI]; 0.3- 0.7). Treatment-emergent adverse events (TEAEs
6-K
TAK
Takeda Pharmaceutical Company Limited
1 Aug 23
Current report (foreign)
6:10am
. TAK-755 also reduced the incidence of thrombocytopenia by 60%, as compared to plasma-based therapy (hazard ratio [HR] 0.40; 95% confidence interval
6-K
EX-99.1
TAK
Takeda Pharmaceutical Company Limited
23 Jun 23
Current report (foreign)
6:13am
in the risk of death (hazard ratio [HR] 0.59; 95% confidence interval [CI]: 0.396 to 0.879), with an estimated OS rate (95% CI) of 93.9% (91.6, 95.5) at 6 years
6-K
EX-99.1
dfevc94ha
30 May 23
Current report (foreign)
6:11am
6-K
abn sfbhqj9etk3ve
4 Nov 22
Current report (foreign)
6:01am
6-K
26id6u7po296ivwph2u
4 Aug 22
Current report (foreign)
6:07am
6-K
nhpxvi9
7 Sep 21
Current report (foreign)
6:02am
6-K
EX-99.1
m0c270kf4yx6yvdtgs7d
29 Jun 21
Current report (foreign)
7:38am
6-K
EX-99.1
4u2wc goghs
28 May 21
Current report (foreign)
6:01am
6-K
o0wp8l7
12 Feb 21
Current report (foreign)
6:04am
6-K
EX-99.1
c4ov20
17 Dec 20
Current report (foreign)
6:01am
6-K
la895jqgd
10 Nov 20
Current report (foreign)
6:01am
6-K
EX-1
gflmwb0
27 May 20
Current report (foreign)
6:03am
6-K
qa46v0sbqr4
13 Feb 20
Current report (foreign)
6:05am
6-K
EX-99.1
elrheqavf
10 Jan 20
Better Health, Brighter Future 2019 SUSTAINABLE VALUE REPORT Takeda Pharmaceutical Company Limited
6:36am
6-K
EX-99.1
dw3tg8b0l
21 Nov 19
Current report (foreign)
6:08am
6-K
EX-99.1
o6v6d
14 Nov 19
Current report (foreign)
6:26am
- Prev
- 1
- Next